SUMMARY Since the great majority of patients possess immune responses to herpes simplex virus (HSV), the influence of a topical anti-inflammatory corticosteroid (0-1 % clobetasone butyrate) on ulcerative herpetic keratitis was studied in rabbits with a previous HSV skin infection (immunised) and compared with that in normal rabbits. Corticosteroid treatment had a much greater ulcerationexacerbating effect in immunised than in normal animals. On day 7 the mean area of ulceration in immunised rabbits was 3 times greater in treated eyes. 0-01 % clobetasone butyrate treatment had less effect on immunised rabbits; 0 001 % had no effect. It is concluded that the immunised rabbit provides a useful experimental model for studying the relationship between concentration of topical anti-inflammatory agents and enhancement of herpetic ulceration.
It is known that the administration of antiinflammatory corticosteroids in ulcerative herpetic keratitis can result in severe exacerbation of disease with the development of geographic or amoeboid ulcers and an increase in the incidence of subsequent complications.' 2 Similar aggravation of herpetic corneal ulceration has been demonstrated in rabbits treated with drugs of this group.3-6 These studies employed normal rabbits which had had no previous contact with herpes simplex virus (HSV), while by contrast the majority of the human population have immune responses to the virus. Since a major effect of corticosteroids is to inhibit immune reactions,7 the use of rabbits with a previous HSV skin infection ('immunised'8) should more closely represent the clinical disease.
The aims of this investigation were to study the effect of a topically administered corticosteroid on ulcerative herpetic keratitis in normal and in immunised rabbits, and to examine the relationship between corticosteroid concentration and degree of enhancement of ulceration. Clobetasone butyrate was used because it is effective in various ocular inflammatory conditions and produces relatively little rise in Fig. 1 ).
In normal rabbits ulcerative disease showed a tendency towards increased severity in the corticosteroid-treated eyes on day 7, the mean areas of ulceration at that time being 32 + 15% (SE) of the cornea in placebo-and 41 + 14% in clobetasone-butyrate-treated eyes (Fig. 2) .
In immunised rabbits a large difference between placebo and corticosteroid-treated eyes was observed. An increase in area of ulceration in clobetasone-butyrate-treated corneas was first seen on day 4, and a very marked difference was found on day 7, when the mean areas of ulceration were 6 +L 5% of the cornea in placeboand 23 + 9% in clobetasone-butyrate-treated eyes. Pooled data from 18 eyes showed a statistically significant increase in areas of ulceration in eyes treated with 0-1 % clobetasone butyrate (p<0 025: rank sum test). At this stage the healing phase of ulcerative disease had already begun in the placebo-treated eyes, while the area of ulceration in corticosteroid-treated corneas was at least that found on day 4. The form of the ulcers was largely geographic, with relatively regular margins. Two animals had large central epithelial defects, where the relative importance of viral infection and self-inflicted abrasive loss of diseased epithelium was not clear. Between days 7 and 9 a reduction in area of ulceration occurred in both placebo-and corticosteroidtreated eyes (Fig. 3) . No differences in CID50 were observed between eyes treated with placebo and with 0 01 % or 0001 % clobetasone butyrate ( Table 1) .
The exacerbating effect of 0-01 % clobetasone butyrate on ulcerative disease was clearly less than that of the 0f1 % preparation. An increase in area of corneal ulceration in the 0-01 % clobetasone-butyrate-compared with the placebotreated eye was seen in 2 of 5 rabbits on day 4 and in 3 of the 4 remaining animals on day 7 (Fig. 4) . Treatment with 0001 % clobetasone butyrate had no discernible effect on the extent ot ulceration at any stage of the infection (Fig. 4) .
Discussion
It may be concluded that clobetasone butyrate nas no effect on initial corneal susceptioility to infection; it produces a considerably greater exacerbation of ulceration in immunised than in normal rabbits; this exacerbation is apparent late in the infection (and delays the initiation of healing); and it is dose-dependent. The lack of any significant effect in normal animals is at variance with the findings of previous studies,3-0 and it might be related to the steroid and schedule used or to the termination of this experiment before the beginning of the healing phase.8 However, it is clear that a much greater enhancement of ulceration occurred in immunised rabbits, and an experimental model employing animals with previous skin or ocular HSV infection provides a close parallel with human disease.8 11 In immunised rabbits a gradation in effect was observed from a distinct exacerbation of ulceration with 0.1 % clobetasone butyrate to an indiscernible effect with the 0-001 % preparation, indicating that the maximum 'safe' concentration in this model lies between 0 01 and 0-001%. Various dilutions of corticosteroid are now used clinically,2 and an understanding of the effects of low concentrations on ulcerative herpetic Fig. 4 
